Quite a number of BET inhibitor titles. However, I didn't see any title for Zenith in the regular abstract titles. It doesn't mean they won't have a clinical trial/late breaking abstract, which haven't been released yet. I didn't see anything for Gilead's GS-5829 or GSK's BET inhibitors, but I may have missed them. The only Zenith hit was for:

1394 / 18 - Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer, in which Irfan A. Asangani of University of Pennsylvania listed Zenith in his disclosures. Academic/Industry collaboration? Consultant? Abstract embargoed for now.

Also of note, Incyte has a title "5793 / 19 - Anti-tumor efficacy of INCB057643, a novel BET bromodomain inhibitor, in castration-resistant prostate cancer as single agent and in combination therapy". Might be related to this clinical trial. Abstract embargoes for now.

Interestingly, looks like Abbvie has a promising BD2 selective compound that they are promoting for its anti-cancer properties. The abstract is embargoed for the first title below but not the second.

800 / 10 - ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia

DDT01-05 - ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor